Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol
UMass Chan Affiliations
UMass Memorial Medical CenterDocument Type
Journal ArticlePublication Date
2004-10-13Keywords
Antineoplastic AgentsColorectal Neoplasms
Desensitization, Immunologic
Dose-Response Relationship, Drug
Drug Hypersensitivity
Female
Humans
Infusions, Intravenous
Middle Aged
Organoplatinum Compounds
effects
Life Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
Oxaliplatin (Eloxatin; Sanofi-Synthelabo Inc.; New York, NY) is a third-generation platinum agent indicated for the treatment of colorectal cancer. Severe hypersensitivity reactions to oxaliplatin rarely occur; however, they do represent a threat to the small number of patients that are occasionally affected. We developed a desensitization protocol and successfully applied it to a patient with severe, grade 3, hypersensitivity to oxaliplatin. For patients who have mild sensitivity to oxaliplatin, slowing the run rate down and giving an antihistamine and/or a steroid usually suffice. Desensitization will help to provide the small number of patients who experience severe hypersensitivity reactions with the ability to further receive an effective therapy for their colorectal cancer. The desensitization protocol is described in detail.Source
Oncologist. 2004;9(5):546-9. Link to article on publisher's siteDOI
10.1634/theoncologist.9-5-546Permanent Link to this Item
http://hdl.handle.net/20.500.14038/38886PubMed ID
15477639Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1634/theoncologist.9-5-546